Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0174 0833 · 1 trial · 1 indication
measured in h·nmol/L
| Arm | Type | Description |
|---|---|---|
| NNC0174 0833 1.8 mg | EXPERIMENTAL | Each participant will receive one single dose of NNC0174 0833 |
| NNC0174 0833 0.9 mg | EXPERIMENTAL | Each participant will receive one single dose of NNC0174 0833 |
| NNC0174 0833 0.3 mg | EXPERIMENTAL | Each participant will receive one single dose of NNC0174 0833 |
| Name | Type | Description |
|---|---|---|
| NNC0174 0833 | DRUG | Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin) |
Key inclusion criteria * Chinese male subject aged 18-55 years (both inclusive) at the time of signing informed consent. * Body mass index (BMI) between 20.0 and 39.9 kg/m\^2 (both inclusive) at screening. * Body weight between 60.0 and 110.0 kg (both inclusive) at screening. Key exclusion criteri...
NNC0174-0833 is an investigational small molecule being developed for the treatment of overweight and obesity, as well as related metabolism and nutrition disorders. It is intended for use in people who are overweight or obese, and clinical studies have included participants with these conditions.
NNC0174-0833 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for weight management.
NNC0174-0833 is in clinical development, with trials completed in Phase 1 and Phase 2. The most advanced study was a Phase 2 trial, which has been completed. The drug is not yet approved and remains investigational, requiring further studies to establish its safety and effectiveness.
NNC0174-0833 has been studied in several completed clinical trials, including NCT02300844, a Phase 1 single-dose study in healthy males; NCT03856047, a Phase 2 efficacy study in overweight or obese individuals; NCT04074174, a drug interaction study with oral contraceptives; and NCT04209049, a pharmacokinetic study in people with normal and impaired kidney function.
NNC0174-0833 is the drug name used in clinical trial registrations, with no alternative names provided in the available data. It is consistently referred to by this identifier across all studies, including those listed on ClinicalTrials.gov.